MedTech case reports: what we did, and what we did not do.

Six engagements, written the way clinical work is documented: the client, the period, EvoMed's exact role, the work, the limits, and the people's own words. Nothing here is a claim we cannot show.

Book a Screening Call Take the Alignment Check

How we write case reports.

A case report on this page follows five rules, and every report is approved by the client before it goes live.

Quotes are printed as the person wrote them; we correct spelling, nothing else, and we date them.
Each report says what EvoMed did in plain verbs, and what it did not do where a reader might assume more.
No outcome appears that the client has not confirmed, and no number appears that cannot be counted on this page.
Where a third party has published something about the work, we link to it instead of describing it.
Companies and programmes are named only with permission; until then they appear anonymised and say so.

Executive medical advisory, monthly retainer

OxyCare: a physician on call for management, product and QM.

Client: OxyCare GmbHBremen, Germany
What they do: Provider of respiratory home care and medical technology: oxygen, sleep therapy, ventilation.
Period: Since 2025, ongoing
EvoMed's role: EvoMed's founder as external medical advisor to management, product management and quality management, with the EvoMed team in support.

What we did

Medical assessments for the reimbursement listing of a cough-assist device in the German medical-aids directory (HMV), across a series of patients, with follow-up supplements in 2026.
Formal specialist opinions on quality and regulatory questions, for example on oxygen supply, written for the client's quality management.
Evaluation of partnership and product candidates from the physician's chair: home FeNO measurement with a return-on-investment recommendation, an inhaler-training device, a digital paediatric asthma therapy, a service concept, sleep-lab shirts.
Prescriber-side tooling: review of the oxygen prescription fill-in guide, answers to prescription questions from the field.
Team training: the annual training days in Bremen with lectures on oxygen therapy, sleep therapy and ventilation for the whole team including new staff, with the decks handed over for internal use.
Medical content for marketing and search: the project on strengthening medical content for search systems, run with OxyCare's online marketing.
One live working session in February 2026 in which EvoMed used several AI tools in real time to build the medical and economic comparison between a ventilator with a pursed-lip-breathing function and devices from OxyCare's own portfolio.

What we did not do

Patient-level data, the individual assessments and the regulatory files stay with OxyCare and are not published here.

Verify: OxyCare GmbH

EvoMed Consulting didn't just advise us on individual questions, they guide us through complexity. Dr. Havkic helped us understand where clinical reality, regulation, and reimbursement truly intersect, and how to make the right decisions at each step. That guidance gave us clarity, confidence, and a much smoother path to adoption.

Pierre LangeGeneral Manager, OxyCare GmbH2026

StarMap Discovery, then follow-on advisory and introductions

Intimka: a founder's first external feedback, then a network.

Client: IntimkaFounder: Natalia Tarasova
What they do: An early-stage digital health venture in intimate health, introduced to EvoMed by Botond Gagyi.
Period: August 2025 to 2026
EvoMed's role: EvoMed's experts, practicing physicians, ran the Discovery; the EvoMed team arranged the introductions.

What we did

7 August 2025: first conversation. The founder describes it as Intimka's very first external feedback and proceeds with StarMap.
13 August 2025: structured self-assessment completed. 14 August 2025: the three-hour CrossCheck session with EvoMed's experts, followed by the written debrief.
September 2025: introductions arranged by EvoMed, a marketing consultant and a specialist physician for the product's clinical question; a legal consultation was attempted.
November 2025: the founder ran the assessment again in StarMap AI on mobile and sent product feedback.
June 2026: catch-up. August 2026: the written testimonial below, sent by email.

What we did not do

EvoMed did not build the product and does not report figures for Intimka; the founder's words stand on their own.

Verify: How StarMap works for founders · The StarMap framework

Working with Amel has been both extremely valuable and genuinely enjoyable. I was able to get clear and thoughtful answers to all of my questions, and his experience helped me anticipate and overcome many of the challenges I could have faced along the way. His insights also became the foundation for several important decisions related to our internal processes and go-to-market strategy. I would definitely recommend speaking with Amel. He not only has a deep understanding of the medical and healthcare space, but also understands how startups grow, the challenges they face, and the practical realities of bringing a new product to market. An additional benefit for me personally is that he is also an excellent networker and has a remarkable ability to connect people and opportunities.

Natalia TarasovaFounder, IntimkaAugust 2026

The most eye-opening insight was realizing how crucial technical integration will be, and which metrics I need to track as soon as I start working with clinics. I now have a clear view of the immediate, mid-term, and long-term steps.

Natalia Tarasovafrom the Discovery debriefSeptember 2025

Clinical medical expert to the QARA team, retainer

Dedalus: the clinical voice in quality and regulatory affairs.

Client: Dedalus HealthCareHealthcare IT, Germany
What they do: One of Europe's largest healthcare software companies; the German organisation builds hospital, radiology and diagnostic imaging IT.
Period: Several years, concluded August 2026
EvoMed's role: EvoMed's founder as the clinical voice inside Quality Assurance and Regulatory Affairs (QARA).

What we did

Patient-safety assessments of reported incidents: clinical evaluation of what happened and whether the product played a role.
Vigilance decisions: assessing whether an incident had to be reported to the authorities, and documenting the clinical reasoning.
Intended-use definitions: clinical input to the intended use of the company's radiology (RIS) and picture-archiving (PACS) systems.
Separately, one working session on the sepsis dashboard: evaluating the clinical logic, which parameters go in and how they are displayed, so the screen follows the intensivist's decision instead of the data source.

What we did not do

EvoMed did not write Dedalus's sepsis publication. It is linked below as the company's own account of the dashboard the session contributed to. Incident details are confidential.

Verify: Dedalus's sepsis dashboard whitepaper (Dennis Rausch, CMO, 2024)

I was impressed with the medical expertise of the EvoMed team and their ability to integrate it seamlessly into our business operations. Their consulting services were invaluable in helping navigate the complex medical imaging diagnostic industry, making our products even more user-friendly and patient-safe.

Davor DadicDirector DIIT, Dedalus2026

Product review from the physician's chair

Eterno CareView: what a doctor looks at, and what he wants to know.

Client: EternoFrankfurt am Main and Hamburg
What they do: Operator of shared medical practice spaces with its own cloud practice software; CareView is its real-time analytics dashboard for practices.
Period: 2024, two reviews
EvoMed's role: EvoMed's founder as a pilot physician in Eterno's Analytics Pioneer programme; his own practice ran on the Eterno platform at the time, which is why he was asked.

What we did

February to March 2024: kick-off and practice benchmarking with Eterno's Chief Data Officer.
June 2024 and October 2024: the two reviews of the analytics product from the physician's perspective, which operational signals a doctor actually reads, what he wants to know first, and what is noise.
January 2025: feedback call on the practice-pulse view before CareView's launch to practice teams in April 2025.

What we did not do

EvoMed did not build CareView and holds no data from it. The product is Eterno's; the link below is Eterno's own page.

Verify: CareView at Eterno

I appreciate working with Dr. Havkic. He consistently manages to bring together medical and business perspectives, and this is also the case with innovative tech topics like analytics.

Bettina GoernerChief Data Officer, Eterno2026

Hospital digitalisation project, before EvoMed

Asklepios: a patient data management system for the ICU.

Client: Asklepios Stadtklinik Bad WildungenBad Wildungen, Germany
What they do: Acute hospital of the Asklepios group.
Period: 2023
EvoMed's role: EvoMed's founder in his hospital role at the time, senior consultant (Leitender Oberarzt) for intensive care and pulmonology, as a member of the project team.

What we did

Introduction of the ICU-Manager, a patient data management system for intensive care, intermediate care, stroke and chest-pain units.
The system records the full course of treatment of every intensive-care patient, including ventilation and vital parameters, medication orders and connected devices, and transfers it automatically into the electronic patient record.
The clinical side of the roll-out on the ward: requirements, workflows, go-live.

What we did not do

This was not an EvoMed engagement. It is the founder's implementation background, included because it is public: the hospital announced it in a press release on 10 August 2023.

Verify: Asklepios press release, 10 August 2023 (in German)

Cohort screening with StarMap

Accelerator cohort: StarMap on live applications.

Client: A life-science accelerator, FrankfurtName published once the programme confirms
What they do: A German life-science accelerator running StarMap on a live cohort.
Period: 2026, in progress
EvoMed's role: EvoMed's experts cross-check every score before it reaches the programme team.

What we did

Applicants complete the structured StarMap assessment; every venture is scored across the seven success factors.
EvoMed's practicing physicians review each score before the programme team sees the cohort view.

What we did not do

No numbers until the programme has ended and the accelerator has approved the report.

Verify: How StarMap works for accelerators

Last reviewed September 2026. 5 quotes from 4 people, all with permission to be named.

Your case

The next report could be yours.

One screening call with EvoMed's experts, practicing physicians, tells you whether StarMap fits your situation. If it does not, we say so.

Book a Screening Call